BioAmp Diagnostics, Inc.

BioAmp Diagnostics focuses on precision diagnostics to address antibiotic resistance, utilizing innovative technology for rapid diagnosis of infections, particularly complicated urinary tract infections (UTIs). BioAmp Diagnostics, Inc. is a specialized diagnostics company founded in 2017 and headquartered in Berkeley, US, dedicated to combating antibiotic resistance. The company was founded by Tara deBoer, who is also the CEO, and has completed one investment deal with its most recent funding round occurring on April 1, 2019.

BioAmp Diagnostics specializes in precision diagnostics aimed at combating antibiotic resistance, primarily through their proprietary diagnostic technology known as DETECT: Dual-Enzyme Trigger-Enabled Cascade Technology. This technology facilitates rapid diagnosis of complicated urinary tract infections (UTIs), allowing healthcare providers to quickly identify appropriate antibiotic treatments, often delivering results in minutes rather than days. The company's services target physicians and healthcare systems in the United States, focusing on optimizing antibiotic prescribing practices to improve patient outcomes and support evidence-based treatment methodologies. BioAmp Diagnostics operates on a B2B model, generating revenue through the direct sale of diagnostic tests powered by their DETECT technology.

This enables healthcare professionals to prescribe the correct antibiotics promptly. The company may partner with hospitals and clinics to offer its diagnostic services, potentially operating under a fee-for-service model where clients pay per test conducted. Their flagship product offerings concentrate on rapid diagnostic solutions for urinary tract infections, fostering an efficient approach to antibiotic stewardship in clinical settings. BioAmp Diagnostics plans to utilize recent funding raised in April 2019 from Blue Bear Ventures to support its growth initiatives.

The company aims to expand its product offerings with new diagnostic solutions and enhance its presence in existing markets. Specific plans include targeting additional healthcare institutions across the United States to increase access to their diagnostic technology. The company is committed to improving antibiotic stewardship and addressing the rising challenge of antibiotic resistance through its innovative diagnostic services.